Trials / Withdrawn
WithdrawnNCT06713798
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study encompasses multicenter open-label, phase II trials. Patients will be dispatched into 2 cohorts: * Cohort A: Patients naïve from systemic treatment will be randomized according to two treatment modalities: atezolizumab + tiragolumab (arm A1) versus atezolizumab monotherapy (arm A2). 43 patients are to be included in each arm. * Cohort B: Patients with previous exposure to ICI will be treated with the combination of atezolizumab and tiragolumab. 29 patients are to be included in this cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab 1200 mg IV | atezolizumab (intravenous 1200mg Q3W) |
| DRUG | Tiragolumab 600 mg IV | Tiragolumab (intravenous 600mg Q3W) |
Timeline
- Start date
- 2025-01-30
- Primary completion
- 2025-09-15
- Completion
- 2025-09-15
- First posted
- 2024-12-03
- Last updated
- 2026-03-23
Source: ClinicalTrials.gov record NCT06713798. Inclusion in this directory is not an endorsement.